

I hereby certify that this correspondence is being  
Electronically Transmitted on the date noted below to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
May 6, 2008

Date of Deposit  
Richard G. Lione, Reg. No. 19,795

Name of applicant, assignee or  
Registered Representative  
/Richard G. Lione/

Signature  
May 6, 2008

Date of Signature

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Hideo Satsu et al.

Appln. No.: 10/579,323

Filed: May 16, 2006

For: IL-8 PRODUCTION  
PROMOTERS AND USE  
THEREOF

Attorney Docket No: 5404/152

Examiner: Michael V. Meller

Art Unit: 1655

Confirmation No. 6569

### SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(c), Applicant hereby cites the following reference(s):

U.S. PATENT DOCUMENTS		
DOCUMENT NUMBER	DATE	NAME
5,900,235	05/04/1999	Gosselin et al.

FOREIGN PATENT DOCUMENTS		
DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY
JP 2003-063991	03/05/2003	Japan

OTHER ART – NON PATENT LITERATURE DOCUMENTS
Djeu, Julie Y., "Functional Activation of Human Neutrophils by Recombinant Monocyte-Derived Neutrophil Chemotactic Factor/IL-8," <i>The Journal of Immunology</i> , Vol. 144, 1990, pp. 2205-2210.

Applicant is enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). Pursuant to the undersigned attorney's obligation and duties under 37 C.F.R. §§ 1.56 and 1.98(a)(3) and (c), either English language abstracts, partial translations, or full translations are included for patent documents which are not in English for the express purpose of providing a concise explanation of the references to the Patent and Trademark Office with the opportunity to evaluate the same. Applicant respectfully requests the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicant is attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

Applicant has calculated a processing fee in the amount of \$180.00 to be due under 37 C.F.R. §1.17(p) in connection with the filing of this Information Disclosure Statement. Applicant has enclosed a check covering this fee, or authorized charging the fee to a deposit account or credit card, as indicated in the Transmittal accompanying this Information Disclosure Statement.

Respectfully submitted,

May 6, 2008  
 \_\_\_\_\_  
 Date

/Richard G. Lione/  
 \_\_\_\_\_  
 Richard G. Lione  
 (Reg. No. 19,795)